Search Results - "Levy, J.H."

Differential diagnoses for sepsis‐induced disseminated intravascular coagulation: communication from the SSC of the ISTH by Iba, T., Levy, J. H., Wada, H., Thachil, J., Warkentin, T. E., Levi, M.

Get full text

Comparison of three‐factor and four‐factor prothrombin complex concentrates regarding reversal of the anticoagulant effects of rivaroxaban in healthy volunteers by Levi, M., Moore, K. T., Castillejos, C. F., Kubitza, D., Berkowitz, S. D., Goldhaber, S. Z., Raghoebar, M., Patel, M. R., Weitz, J. I., Levy, J. H.

“…Summary Background Four‐factor prothrombin complex concentrates (PCCs), which contain factor II, FVII, FIX, and FX, have shown the potential to reverse the…”
Get full text

Randomized evaluation of fibrinogen vs placebo in complex cardiovascular surgery (REPLACE): a double-blind phase III study of haemostatic therapy by Rahe-Meyer, N., Levy, J.H., Mazer, C.D., Schramko, A., Klein, A.A., Brat, R., Okita, Y., Ueda, Y., Schmidt, D.S., Ranganath, R., Gill, R.

“…Single-dose human fibrinogen concentrate (FCH) might have haemostatic benefits in complex cardiovascular surgery. Patients undergoing elective aortic surgery…”
Get full text

Finding the optimal concentration range for fibrinogen replacement after severe haemodilution: an in vitro model by Bolliger, D., Szlam, F., Molinaro, R.J., Rahe-Meyer, N., Levy, J.H., Tanaka, K.A.

“…Replacement of fibrinogen is presumably the key step in managing dilutional coagulopathy. We performed an in vitro study hypothesizing that there is a minimal…”
Get full text

Addressing the question of the effect of RBC storage on clinical outcomes: The Red Cell Storage Duration Study (RECESS) (Section 7) by Steiner, M.E, Assmann, S.F, Levy, J.H, Marshall, J, Pulkrabek, S, Sloan, S.R, Triulzi, D, Stowell, C.P

“…Abstract The question of whether storage of red blood cells (RBCs) alters their capacity to deliver oxygen and affects patient outcomes remains in a state of…”
Get full text

Recombinant human antithrombin III restores heparin responsiveness and decreases activation of coagulation in heparin-resistant patients during cardiopulmonary bypass by Avidan, M.S., Levy, J.H., van Aken, H., Feneck, R.O., Latimer, R.D., Ott, E., Martin, E., Birnbaum, D.E., Bonfiglio, L.J., Kajdasz, D.K., Despotis, G.J.

“…We sought to evaluate the efficacy of recombinant human antithrombin III for restoration of heparin responsiveness in heparin-resistant patients scheduled for…”
Get full text

Inflammation and thrombosis: roles of neutrophils, platelets and endothelial cells and their interactions in thrombus formation during sepsis by Iba, T., Levy, J. H.

“…Summary The inflammatory response and the activation of coagulation are two important responses in a host's defense against infection. These mechanisms do not…”
Get full text

Derangement of the endothelial glycocalyx in sepsis by Iba, T., Levy, J. H.

“…Summary The vascular endothelial surface is coated by the glycocalyx, a ubiquitous gel‐like layer composed of a membrane‐binding domain that contains…”
Get full text

Inhibition of complement activation by pexelizumab reduces death in patients undergoing combined aortic valve replacement and coronary artery bypass surgery by Carrier, M., Ménasché, P., Levy, J.H., Newman, M.F., Taylor, K.M., Haverich, A., Chen, J.C., Shernan, S.K., Van de Werf, F., van der Laan, M., Todaro, T.G., Adams, P.X., Verrier, E.D.

“…We sought to evaluate the effects of pexelizumab, a C5 complement inhibitor, on death and myocardial infarction in patients undergoing combined aortic valve…”
Get full text

Prostate and Bladder Segmentation Using a Statistically Trainable Model by Levy, J.H, Broadhurst, R.E, Jeong, J, Liu, X, Stough, J, Tracton, G.S, Pizer, S.M, Chaney, E.L

Get full text

Perioperative management of the bleeding patient by Ghadimi, K, Levy, J.H., Welsby, I.J.

“…Perioperative bleeding remains a major complication during and after surgery, resulting in increased morbidity and mortality. The principal causes of…”
Get full text

When and how to use antidotes for the reversal of direct oral anticoagulants: guidance from the SSC of the ISTH by Levy, J. H., Ageno, W., Chan, N. C., Crowther, M., Verhamme, P., Weitz, J. I.

Get full text

Cryoprecipitate therapy by Nascimento, B., Goodnough, L.T., Levy, J.H.

“…Cryoprecipitate, originally developed as a therapy for patients with antihaemophilic factor deficiency, or haemophilia A, has been in use for almost 50 yr…”
Get full text

Use of factor concentrates for the management of perioperative bleeding: guidance from the SSC of the ISTH by Godier, A., Greinacher, A., Faraoni, D., Levy, J. H., Samama, C. M.

Get full text

The recommended dose of idarucizumab may not always be sufficient for sustained reversal of dabigatran by Simon, A., Domanovits, H., Ay, C., Sengoelge, G., Levy, J. H., Spiel, A. O.

“…Essentials Reversal of anticoagulant effects of dabigatran may occur despite application of idarucizumab. Monitoring of dabigatran level after antidote…”
Get full text

Impact of High-Dose Prophylactic Anticoagulation in Critically Ill Patients With COVID-19 Pneumonia by Tacquard, Charles, Mansour, Alexandre, Godon, Alexandre, Godet, Julien, Poissy, Julien, Garrigue, Delphine, Kipnis, Eric, Rym Hamada, Sophie, Mertes, Paul Michel, Steib, Annick, Ulliel-Roche, Mathilde, Bouhemad, Bélaïd, Nguyen, Maxime, Reizine, Florian, Gouin-Thibault, Isabelle, Besse, Marie Charlotte, Collercandy, Nived, Mankikian, Stefan, Levy, Jerrold H., Gruel, Yves, Albaladejo, Pierre, Susen, Sophie, Godier, Anne, Albaladejo, P., Blais, N., Bonhomme, F., Borel-Derlon, A., Cohen, A., Collet, J.-P., de Maistre, E., Fontana, P., Garrigue Huet, D., Godier, A., Gruel, Y., Godon, A., Ickx, B., Laporte, S., Lasne, D., Llau, J., Le Gal, G., Lecompte, T., Lessire, S., Levy, J.H., Longrois, D., Madi-Jebara, S., Mansour, A., Mazighi, M., Mismetti, P., Morange, P.E., Motte, S., Mullier, F., Nathan, N., Nguyen, P., Pernod, G., Rosencher, N., Roullet, S., Roy, P.M., Schlumberger, S., Sié, P., Steib, A., Susen, S., Tacquard, C.A., Testa, S., Vincentelli, A., Zufferey, P.

“…Because of the high risk of thrombotic complications (TCs) during SARS-CoV-2 infection, several scientific societies have proposed to increase the dose of…”
Get full text

Rivaroxaban reversal with prothrombin complex concentrate or tranexamic acid in healthy volunteers by Levy, J. H., Moore, K. T., Neal, M. D., Schneider, D., Marcsisin, V. S., Ariyawansa, J., Weitz, J. I.

“…Essentials Specific reversal agents for managing severe factor Xa inhibitor‐associated bleeding are lacking. We assessed 4‐factor‐prothrombin complex…”
Get full text

Perioperative Considerations in Management of the Severely Bleeding Coagulopathic Patient by Erdoes, G., Faraoni, D., Koster, A., Steiner, M.E., Ghadimi, K., Levy, J.H.

“…( Anesthesiology. 2023; 138:535–560) This clinical review explored coagulopathy in severely bleeding patients after major surgery (eg, cardiac surgery with…”
Get full text

Inhaled Selective Pulmonary Vasodilators for Advanced Heart Failure Therapies by Ghadimi, K., Cappiello, J., Cooter, M., Levy, J.H., Schroder, J.N., Bryner, B., Shah, S.H., Rajagopal, S., Devore, A.D., Patel, C.B., Milano, C.A.

“…Inhaled pulmonary vasodilators (iPVD) are commonly used to lower PVR to modify the risk of acute RV failure in durable LVAD implantation or orthotopic heart…”
Get full text

Inhaled Selective Pulmonary Vasodilators for Adult Lung Transplantation by Ghadimi, K., Cappiello, J., Cooter, M., Haney, J., Reynolds, J., Bottiger, B.A., Klapper, J., McLendon-Arvik, B., Levy, J.H., Hartwig, M.G.

“…Inhaled pulmonary vasodilators (iPVD) are commonly used in lung transplant recipients to mitigate the risk of primary graft dysfunction (PGD). While inhaled…”
Get full text